Baisch H, Otto U, Klöppel G
Institute of Biophysics and Radiobiology, University of Hamburg, Federal Republic of Germany.
Cancer Res. 1990 Oct 1;50(19):6389-95.
A human renal cell carcinoma serially transplanted into nude mice was treated with recombinant human tumor necrosis factor alpha (TNF-alpha), recombinant human alpha interferon (IFN-alpha), and a combination of both. All treatments resulted in a significantly reduced tumor growth. The greatest effect was obtained with the combination of TNF-alpha and IFN-alpha. This latter treatment completely eradicated tumors which were smaller than 50 mm3 at the beginning of treatment. Cell kinetic analysis using the bromodeoxyuridine technique and flow cytometry revealed a prolongation of the transition time through S-phase from 7.9 h in the case of control tumors to 10.5 h for tumors treated with IFN-alpha and TNF-alpha. Single treatment with either TNF-alpha or IFN-alpha had only minor effects. The bromodeoxyuridine labeling index was unaffected by IFN-alpha (16.6%; control, 15.2%) but was reduced to 12.1 and 11.7% when tumors were treated with TNF-alpha and IFN-alpha plus TNF-alpha, respectively. The calculated potential doubling times were 2.3 and 2.8 days, respectively, for tumors treated with TNF-alpha or IFN-alpha plus TNF-alpha. When treated with IFN-alpha, the potential doubling time (1.7 days) was similar to that of the control (1.6 days), indicating that the main effect of TNF-alpha was antiproliferative. Conversely, the calculated cell loss factors increased after IFN-alpha and combined treatment but not after TNF-alpha treatment. Combined treatment augmented cytotoxicity, but the cell kinetic characteristics of surviving cells remained similar to those of tumors treated with TNF-alpha alone. Histological analysis showed a distinctly reduced mitotic activity but no coagulative necroses after treatment with TNF-alpha. IFN-alpha and, in particular, IFN-alpha plus TNF-alpha induced cytoplasmic vacuolization, nuclear pyknosis, and cell death, which resulted in tumor regression. These data suggest that, in this particular tumor model, TNF-alpha produces mainly antiproliferative effects, whereas IFN-alpha acts via cytotoxic mechanisms.
将人肾细胞癌连续移植到裸鼠体内,分别用重组人肿瘤坏死因子α(TNF-α)、重组人α干扰素(IFN-α)以及二者联合进行治疗。所有治疗均使肿瘤生长显著减缓。TNF-α与IFN-α联合治疗效果最佳。该联合治疗完全根除了治疗开始时体积小于50立方毫米的肿瘤。采用溴脱氧尿苷技术和流式细胞术进行的细胞动力学分析显示,从S期的过渡时间从对照肿瘤的7.9小时延长至经IFN-α和TNF-α治疗的肿瘤的10.5小时。单独使用TNF-α或IFN-α治疗仅有轻微效果。溴脱氧尿苷标记指数不受IFN-α影响(16.6%;对照为15.2%),但在用TNF-α以及IFN-α加TNF-α治疗肿瘤时,该指数分别降至12.1%和11.7%。经TNF-α或IFN-α加TNF-α治疗的肿瘤,其计算得出的潜在倍增时间分别为2.3天和2.8天。用IFN-α治疗时,潜在倍增时间(1.7天)与对照(1.6天)相似,表明TNF-α的主要作用是抗增殖。相反,IFN-α治疗及联合治疗后计算得出的细胞丢失因子增加,而TNF-α治疗后未增加。联合治疗增强了细胞毒性,但存活细胞的细胞动力学特征仍与单独用TNF-α治疗的肿瘤相似。组织学分析显示,TNF-α治疗后有丝分裂活性明显降低,但无凝固性坏死。IFN-α,尤其是IFN-α加TNF-α诱导细胞质空泡化、核固缩和细胞死亡,从而导致肿瘤消退。这些数据表明,在这个特定的肿瘤模型中,TNF-α主要产生抗增殖作用,而IFN-α通过细胞毒性机制发挥作用。